This retrospective look at 142 cases of metastatic melanoma treated with immune checkpoint inhibition with available primary tumor biopsy specimens analyzed for tumor-infiltrating lymphocytes (TILs) reports 32% had absent TILs, 56% present but non-brisk TILs, and 11 brisk TILs. Those with absent versus any TILs had double the odds of progression. On the other hand, there was no clear distinction between non-brisk versus brisk TILs, likely due to small numbers. The authors conclude: “Pathologists should consider including TILs classification in diagnostic reports if they do not already.” | Stephens, JAMA Dermatol 2022


Popular Posts